Treatment for Tibial Plateau Fracture
Phase-Based Progress Estimates
Effectiveness
Safety
University of Utah Orthopaedic Center, Salt Lake City, UT
Tibial Plateau Fracture+4 MoreEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
The purpose of this study is to evaluate both genotypic differences and differences in local gene expression in individuals who develop acute traumatic compartment syndrome relative to control patients with at-risk lower extremity fractures who do not develop compartment syndrome.
Eligible Conditions
- Tibial Plateau Fracture
- Tibial Shaft Fractures
Treatment Effectiveness
Effectiveness Progress
Other trials for Tibial Plateau Fracture
Study Objectives
1 Primary · 0 Secondary · Reporting Duration: Immediately after the muscle tissue harvest procedure.
Immediately after the muscle tissue harvest procedure.
Myostatin (% increase)
Trial Safety
Safety Progress
Other trials for Tibial Plateau Fracture
Trial Design
0 Treatment Group
80 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · No Placebo Group · N/A
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: immediately after the muscle tissue harvest procedure.
Trial Background
Justin Haller, Principle Investigator
Principal Investigator
University of Utah
Closest Location: University of Utah Orthopaedic Center · Salt Lake City, UT
2019First Recorded Clinical Trial
1 TrialsResearching Tibial Plateau Fracture
15 CompletedClinical Trials
Eligibility Criteria
Age 18+ · All Participants · 4 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have a patient who is 18 years of age or older
Patients without clinical compartment syndrome undergoing operative intervention within 48 hours of injury for tibial shaft or tibial plateau fractures.
You have a clinical diagnosis of lower leg acute compartment syndrome secondary to tibial shaft or tibial plateau fracture.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Popular Clinical Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments